Duloxetine Capsule, Delayed Release
Product Images NDC 50090-7784

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-7784). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)

Duloxetine 30 mg delayed-release capsules in a blister pack. The package contains multiple capsules arranged in two columns with black capsules encased in clear plastic on a white backing. The labeler is A-S Medication Solutions.*

FDA Label Image

Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)

Chemical structure diagram of duloxetine hydrochloride, showing its bicyclic benzene and thiophene rings connected through a chiral oxygen, with an attached methylaminoethyl side chain and hydrochloride.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)

A Kaplan-Meier curve chart comparing the proportion of patients with relapse over time in days from randomization. The chart shows two treatment groups: Placebo (dashed line) and Duloxetine (solid line). The y-axis represents the proportion of patients with relapse, and the x-axis represents time in days, up to 200 days.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)

A Kaplan-Meier estimator curve graph showing the proportion of patients with relapse over time (days) from randomization. The graph compares two treatments: placebo represented by a dashed line and duloxetine represented by a solid line, with duloxetine showing a lower relapse proportion over time.*

FDA Label Image

Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. Four lines represent different treatments: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and placebo. The graph compares pain improvement outcomes among these groups across varying levels of pain reduction.*

FDA Label Image

Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)

A line graph showing the percentage of patients improved on the y-axis versus the percent improvement in pain from baseline on the x-axis. The graph compares Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo groups, with data points marked for each group and a legend identifying the lines.*

FDA Label Image

Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)

A line graph showing percentage of patients improved versus percent improvement in pain from baseline. Three groups are depicted: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and Placebo, with the Duloxetine groups showing higher percentages of improvement across pain thresholds compared to placebo.*

FDA Label Image

Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)

A line graph showing the percentage of patients improved relative to percent improvement in pain from baseline. The graph compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two series), and placebo, illustrating the trend of patient improvement across increasing levels of pain reduction.*

FDA Label Image

Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)

A line graph comparing the percentage of pediatric patients aged 13 to 17 years with Juvenile Fibromyalgia Syndrome achieving various levels of pain relief at week 12. The x-axis represents percent improvement in pain from baseline, ranging from greater than 0 to 100 percent. The y-axis shows the percentage of patients improved, from 0 to 100 percent. Two lines compare Duloxetine 60 mg once daily versus placebo, with the Duloxetine group consistently showing higher percentages of patient improvement across pain relief levels.*

FDA Label Image

Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)

A line graph comparing percentage of patients improved against percent improvement in pain from baseline (BOCF) for Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain, and the y-axis shows percentage of patients improved. Two lines represent Duloxetine and placebo, with Duloxetine consistently showing higher patient improvement percentages across the range.*

FDA Label Image

Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo across various percent improvement thresholds in pain from baseline. The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Two lines illustrate higher patient improvement percentages with Duloxetine compared to placebo.*

FDA Label Image

Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It compares two groups: placebo and Duloxetine 60/120 mg once daily, showing higher patient improvement percentages for Duloxetine across various pain improvement levels.*

FDA Label Image

Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)

Duloxetine 30 mg delayed-release capsules packaging label from A-S Medication Solutions. The label shows a blister pack containing white and black capsules arranged in two vertical rows of six. The capsules appear uniformly designed without additional markings visible on them.*

FDA Label Image

Label Image (Lbl500907784)

Duloxetine 30 mg delayed-release capsules label, produced by A-S Medication Solutions. The label indicates each capsule contains duloxetine hydrochloride equivalent to 30 mg of duloxetine. The package contains 90 capsules and includes storage instructions to keep at 77 degrees Fahrenheit. The NDC is 50090-7784.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.